Literature DB >> 8755600

Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells.

S Efthimiopoulos1, D Vassilacopoulou, J A Ripellino, N Tezapsidis, N K Robakis.   

Abstract

The Abeta peptide of Alzheimer disease is derived from the proteolytic processing of the amyloid precursor proteins (APP), which are considered type I transmembrane glycoproteins. Recently, however, soluble forms of full-length APP were also detected in several systems including chromaffin granules. In this report we used antisera specific for the cytoplasmic sequence of APP to show that primary bovine chromaffin cells secrete a soluble APP, termed solAPPcyt, of an apparent molecular mass of 130 kDa. This APP was oversecreted from Chinese hamster ovary cells transfected with a full-length APP cDNA indicating that solAPPcyt contained both the transmembrane and Abeta sequence. Deglycosylation of solAPPcyt showed that it contained both N- and O-linked sugars, suggesting that this APP was transported through the endoplasmic reticulum-Golgi pathway. Secretion of solAPPcyt from primary chromatin cells was temperature-, time-, and energy-dependent and was stimulated by cell depolarization in a Ca2+-dependent manner. Cholinergic receptor agonists, including acetylcholine, nicotine, or carbachol, stimulated the rapid secretion of solAPPcyt, a process that was inhibited by cholinergic antagonists. Stimulation of solAPPcyt secretion was paralleled by a stimulation of secretion in catecholamines and chromogranin A, indicating that secretion of solAPPcyt was mediated by chromaffin granule vesicles. Taken together, our results show that release of the potentially amyloidogenic solAPPcyt is an active cellular process mediated by both the constitutive and regulated pathways. solAPPcyt was also detected in human cerebrospinal fluid. Combined with the neuronal physiology of chromaffin cells, our data suggest that cholinergic agonists may stimulate the release of this APP in neuronal synapses where it may exert its biological functions. Moreover, vesicular or secreted solAPPcyt may serve as a soluble precursor of Abeta.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755600      PMCID: PMC38872          DOI: 10.1073/pnas.93.15.8046

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

Review 1.  beta-Amyloid, protein processing and Alzheimer's disease.

Authors:  C Haas; A Y Hung; M Citron; D B Teplow; D J Selkoe
Journal:  Arzneimittelforschung       Date:  1995-03

Review 2.  Involvement of amyloid as a central step in the development of Alzheimer's disease.

Authors:  N K Robakis; M N Pangalos
Journal:  Neurobiol Aging       Date:  1994       Impact factor: 4.673

Review 3.  Is amyloid causally involved in pathophysiology of Alzheimer's disease?

Authors:  T Saitoh; K Brugge
Journal:  Neurobiol Aging       Date:  1994 Jul-Aug       Impact factor: 4.673

4.  Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP).

Authors:  H H Slunt; G Thinakaran; C Von Koch; A C Lo; R E Tanzi; S S Sisodia
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

5.  Chromaffin cells express Alzheimer amyloid precursor protein in the same manner as brain cells.

Authors:  M Takeda; S Tanaka; H Kido; S Daikoku; M Oka; K Sakai; N Katunuma
Journal:  Neurosci Lett       Date:  1994-02-28       Impact factor: 3.046

6.  Full-length and truncated Alzheimer amyloid precursors in chromaffin granules: solubilization of membrane amyloid precursor is mediated by an enzymatic mechanism.

Authors:  D Vassilacopoulou; J A Ripellino; N Tezapsidis; V Y Hook; N K Robakis
Journal:  J Neurochem       Date:  1995-05       Impact factor: 5.372

7.  Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein.

Authors:  K Furukawa; S W Barger; E M Blalock; M P Mattson
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

8.  Solubilization of full-length amyloid precursor proteins from PC12 cell membranes.

Authors:  J A Ripellino; D Vassilacopoulou; N K Robakis
Journal:  J Neurosci Res       Date:  1994-10-01       Impact factor: 4.164

9.  Intracellular routing of human amyloid protein precursor: axonal delivery followed by transport to the dendrites.

Authors:  M Simons; E Ikonen; P J Tienari; A Cid-Arregui; U Mönning; K Beyreuther; C G Dotti
Journal:  J Neurosci Res       Date:  1995-05-01       Impact factor: 4.164

10.  The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway.

Authors:  C Haass; C A Lemere; A Capell; M Citron; P Seubert; D Schenk; L Lannfelt; D J Selkoe
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

View more
  22 in total

Review 1.  Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

Authors:  Vivian Hook; Gregory Hook; Mark Kindy
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

Review 2.  Protease pathways in peptide neurotransmission and neurodegenerative diseases.

Authors:  Vivian Y H Hook
Journal:  Cell Mol Neurobiol       Date:  2006-05-25       Impact factor: 5.046

3.  Allelic variation of calsyntenin 2 (CLSTN2) modulates the impact of developmental tobacco smoke exposure on mnemonic processing in adolescents.

Authors:  Leslie K Jacobsen; Marina R Picciotto; Christopher J Heath; W Einar Mencl; Joel Gelernter
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

4.  Specific amyloid β clearance by a catalytic antibody construct.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Sari Sonoda; Yan Lin; Hiroaki Taguchi; Mariko Hara; Steven Kolodziej; Yukie Mitsuda; Veronica Gonzalez; Hameetha B R Sait; Ken-ichiro Fukuchi; Richard J Massey; Robert P Friedland; Brian O'Nuallain; Einar M Sigurdsson; Sudhir Paul
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 5.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

Review 6.  Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease.

Authors:  Vivian Hook; Lydiane Funkelstein; Jill Wegrzyn; Steven Bark; Mark Kindy; Gregory Hook
Journal:  Biochim Biophys Acta       Date:  2011-09-08

Review 7.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

8.  CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.

Authors:  Wei Tang; Yan Wang; Juan Cheng; Jie Yao; Yu-You Yao; Qiang Zhou; Shi-He Guan
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

9.  Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.

Authors:  Thomas Toneff; Lydiane Funkelstein; Charles Mosier; Armen Abagyan; Michael Ziegler; Vivian Hook
Journal:  Peptides       Date:  2013-06-06       Impact factor: 3.750

10.  Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.

Authors:  María-Ximena Silveyra; Geneviève Evin; María-Fernanda Montenegro; Cecilio J Vidal; Salvador Martínez; Janetta G Culvenor; Javier Sáez-Valero
Journal:  Mol Cell Biol       Date:  2008-02-25       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.